journal article·2025-03-20Open access

Evaluating the Link Between Cardiovascular Risk and Alzheimer’s Disease: A Comprehensive Case-Control Study in Castilla y León, Spain

Laura Bello-Corral, Jesús Seco-Calvo, Marta Celorrio San Miguel, Evelina Garrosa, Diego Fernández-Lázaro, Leticia Sánchez-Valdeón

Applied Sciences· Volume 15· Issue 6

Abstract

Alzheimer’s disease (AD) represents a growing public health challenge due to its increasing prevalence, projected to reach 150 million cases by 2050. Characterised by neuropathological changes such as the accumulation of beta-amyloid peptide and hyperphosphorylated Tau protein, the disease is related to genetic and environmental factors. The main objective of this research has been to analyse the possible relationship between some cardiovascular factors and AD. This analytical observational case-control study carried out in Castilla y León (Spain), comprised a total of 511 individuals between 60 and 90 years of age, of whom 260 had a diagnosis of AD and the rest were healthy individuals. The results showed that the group with AD were predominantly women, widowed and with primary education, who showed a higher prevalence of family history of the disease. It was also observed that hypertension, cardiac pathology and diabetes mellitus were three cardiovascular risk factors that showed significant increased differences in the group of AD patients compared to the group of control individuals. Although the precise mechanisms require further research, these results underline the importance of addressing complex interactions between genetic and environmental factors in the prevention of AD.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Dementia and Cognitive Impairment Research · Blood Pressure and Hypertension Studies · Nutritional Studies and Diet

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Health Research Nursing Group (GREIS), University of Leon, 24071 Leon, Spain

Department of Nursing and Physiotherapy, University of Leon, 24071 Leon, Spain

Institute of Biomedicine, University of Leon, 24071 Leon, Spain

Department of Physiology, University of the Basque Country, 48940 Leioa, Spain

Emergency Department, Línea de la Concepción Hospital, C. Gabriel Miró, 108, 11300 La Línea de la Concepción, Spain

Faculty of Psychology, University of Salamanca, 37007 Salamanca, Spain

Department of Cellular Biology, Genetics, Histology and Pharmacology, Faculty of Health Sciences, University of Valladolid, Campus of Soria, 42004 Soria, Spain

Neurobiology Research Group, Faculty of Medicine, University of Valladolid, 37007 Valladolid, Spain

Funding

Department of Education of the Junta de Castilla & León and the European Regional Development Fund (ERDF) by TCUE Plan 2024–2028 · Consejo General de Enfermería

References (79)

Show source-provided references
1. The Public Health Road Map to Respond to the Growing Dementia Crisis10.1093/geroni/igz043 ↗
2. La historia olvidada del alzhéimer: Recordando a Oskar Fischer
3. The Lancet Commission on Dementia Prevention, Intervention, and Care: A call for action10.1017/ipm.2018.4 ↗
4. The neuropathological diagnosis of Alzheimer’s disease10.1186/s13024-019-0333-5 ↗
5. Extracellular protein components of amyloid plaques and their roles in Alzheimer’s disease pathology10.1186/s13024-021-00465-0 ↗
6. Teleanu, D.M., Niculescu, A.G., Lungu, I.I., Radu, C.I., Vladâcenco, O., Roza, E., Costăchescu, B., Grumezescu, A.M., and Teleanu, R.I. (2022). An Overview of Oxidative Stress, Neuroinflammation, and Neurodegenerative Diseases. Int. J. Mol. Sci., 23.10.3390/ijms23115938 ↗
7. Gene–environment interactions in Alzheimer disease: The emerging role of epigenetics10.1038/s41582-022-00714-w ↗
8. Epigenetic biomarkers in Alzheimer’s disease: Diagnostic and prognostic relevance10.1016/j.arr.2024.102556 ↗
9. Bello-Corral, L., Seco-Calvo, J., Molina Fresno, A., González, A.I., Llorente, A., Fernández-Lázaro, D., and Sánchez-Valdeón, L. (2024). Prevalence of ApoE Alleles in a Spanish Population of Patients with a Clinical Diagnosis of Alzheimer’s Disease: An Observational Case-Control Study. Medicina, 60.10.3390/medicina60121941 ↗
10. Modifiable, Non-Modifiable, and Clinical Factors Associated with Progression of Alzheimer’s Disease10.3233/JAD-201182 ↗
11. Modifiable Risk Factors in Alzheimer Disease and Related Dementias: A Review10.1016/j.clinthera.2021.05.006 ↗
12. The projected effect of risk factor reduction on Alzheimer’s disease prevalence10.1016/S1474-4422(11)70072-2 ↗
13. The role of nutrition in Alzheimer’s disease
14. Exercise benefits on Alzheimer’s disease: State-of-the-science10.1016/j.arr.2020.101108 ↗
15. Alzheimer’s dementia: Pathogenesis and impact of cardiovascular risk factors on cognitive decline10.1080/00325481.2019.1657776 ↗
16. Soluble and insoluble protein aggregates, endoplasmic reticulum stress, and vascular dysfunction in Alzheimer’s disease and cardiovascular diseases10.1007/s11357-023-00748-y ↗
17. The Links between Cardiovascular Diseases and Alzheimer’s Disease10.2174/18756190MTA4dNjE52 ↗
18. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies10.7326/0003-4819-147-8-200710160-00010 ↗
19. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences10.3758/BF03193146 ↗
20. Sample size, power and effect size revisited: Simplified and practical approaches in pre-clinical, clinical and laboratory studies10.11613/BM.2021.010502 ↗
21. (2013). World Medical Association World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA, 310, 2191–2194.10.1001/jama.2013.281053 ↗
22. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease10.1016/j.jalz.2011.03.004 ↗
23. International Classification of Diseases—11th revision: From design to implementation
24. Role of primary aging hallmarks in Alzheimer’s disease10.7150/thno.79535 ↗
25. José, M., Fructuoso, P., García Revilla, R., Moure, O.M., and Moure, R.C. (2025). Analysis of Aging in Spain: Contemporary Sociological and Demographic Implications. Societies, 15.10.3390/soc15020046 ↗
26. Riedel, B.C., Thompson, P.M., and Brinton, R.D. (2016). Age, APOE and Sex: Triad of Risk of Alzheimer’s Disease. J. Steroid Biochem. Mol. Biol., 160.10.1016/j.jsbmb.2016.03.012 ↗
27. Aging and Alzheimer’s disease: Comparison and associations from molecular to system level10.1111/acel.12802 ↗
28. Azam, S., Haque, M.E., Balakrishnan, R., Kim, I.S., and Choi, D.K. (2021). The Ageing Brain: Molecular and Cellular Basis of Neurodegeneration. Front. Cell Dev. Biol., 9.10.3389/fcell.2021.683459 ↗
29. Fernández-Lázaro, D., Garrosa, E., Seco-Calvo, J., and Garrosa, M. (2022). Potential Satellite Cell-Linked Biomarkers in Aging Skeletal Muscle Tissue: Proteomics and Proteogenomics to Monitor Sarcopenia. Proteomes, 10.10.3390/proteomes10030029 ↗
30. Alzheimer’s disease as a women’s health challenge: A call for action on integrative precision medicine approaches10.1038/s44294-024-00021-3 ↗
31. Di Sex difference in biological change and mechanism of Alzheimer’s disease: From macro- to micro-landscape10.1016/j.arr.2023.101918 ↗
32. Mechanisms of sex differences in Alzheimer’s disease10.1016/j.neuron.2024.01.024 ↗
33. Alzheimer’s pathogenic mechanisms and underlying sex difference10.1007/s00018-021-03830-w ↗
34. Calvo, N., and Einstein, G. (2023). Steroid hormones: Risk and resilience in women’s Alzheimer disease. Front. Aging Neurosci., 15.10.3389/fnagi.2023.1159435 ↗
35. Sex differences in brain aging among adults with family history of Alzheimer’s disease and APOE4 genetic risk10.1016/j.nicl.2021.102620 ↗
36. Sex differences in the clinical manifestations of Alzheimer disease pathology10.1001/archpsyc.62.6.685 ↗
37. Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer’s disease: Findings from three well-characterized cohorts10.1016/j.jalz.2018.04.010 ↗
38. The effect of the age at school entry on educational attainment and field of study: An analysis using the Spanish census10.1007/s10734-023-01053-5 ↗
39. Education reduces cognitive dysfunction in Alzheimer’s disease by changing regional cerebral perfusion: An in-vivo arterial spin labeling study10.1007/s10072-023-06696-x ↗
40. Educational attainment, structural brain reserve and Alzheimer’s disease: A Mendelian randomization analysis10.1093/brain/awac392 ↗
41. Modifiable pathways in Alzheimer’s disease: Mendelian randomisation analysis10.1136/bmj.j5375 ↗
42. Cognitive performance protects against Alzheimer’s disease independently of educational attainment and intelligence10.1038/s41380-022-01695-4 ↗
43. Summative Effects of Vascular Risk Factors on the Progression of Alzheimer Disease10.1111/jgs.16181 ↗
44. Age, Vascular Health, and Alzheimer’s disease Biomarkers in an Elderly Sample10.1002/ana.25071 ↗
45. Hypertension induces brain β-amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature10.1161/HYPERTENSIONAHA.112.195511 ↗
46. Relationship between blood pressure and Alzheimer’s disease in Linxian County, China10.1016/S0024-3205(02)02367-6 ↗
47. Diabetes and hypertension are related to amyloid-beta burden in the population-based Rotterdam Study10.1093/brain/awac354 ↗
48. Meta-analysis of modifiable risk factors for Alzheimer’s disease
49. Blood Pressure and Risks of Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis of 209 Prospective Studies10.1161/HYPERTENSIONAHA.120.14993 ↗
50. Efectos del tratamiento y las drogas anti-hipertensivas sobre la función cognitiva: Deterioro cognitivo, demencia y enfermedad de Alzheimer
51. Risk factors for β-amyloid deposition in healthy aging: Vascular and genetic effects10.1001/jamaneurol.2013.1342 ↗
52. Hypertension and longitudinal changes in cerebral blood flow: The SMART-MR study10.1002/ana.23554 ↗
53. Rationale and Design of the Mechanistic Potential of Antihypertensives in Preclinical Alzheimer’s (HEART) Trial10.3233/JAD-161198 ↗
54. Testa, G., Giannelli, S., Staurenghi, E., Cecci, R., Floro, L., Gamba, P., Sottero, B., and Leonarduzzi, G. (2024). The Emerging Role of PCSK9 in the Pathogenesis of Alzheimer’s Disease: A Possible Target for the Disease Treatment. Int. J. Mol. Sci., 25.10.3390/ijms252413637 ↗
55. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study10.1161/01.ATV.20.10.2255 ↗
56. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer’s disease10.1159/000026149 ↗
57. Association of Hypercholesterolemia with Alzheimer’s Disease Pathology and Cerebral Amyloid Angiopathy10.3233/JAD-191023 ↗
58. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease10.7326/0003-4819-137-3-200208060-00006 ↗
59. Effects of hypertension and hypercholesterolemia on cognitive functioning in patients with alzheimer disease10.1097/WAD.0b013e318188e80d ↗
60. Hypercholesterolemia and Alzheimer’s Disease: Unraveling the Connection and Assessing the Efficacy of Lipid-Lowering Therapies10.3233/JAD-240388 ↗
61. O’Connell, E.M., and Lohoff, F.W. (2020). Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders. Front. Neurosci., 14.10.3389/fnins.2020.00609 ↗
62. Heart failure and Alzheimer’s disease10.1111/joim.12287 ↗
63. Al-Kuraishy, H.M., Sulaiman, G.M., Mohammed, H.A., Mohammed, S.G., Al-Gareeb, A.I., Albuhadily, A.K., Dawood, R.A., Al Ali, A., and Abu-Alghayth, M.H. (2025). Amyloid-β and heart failure in Alzheimer’s disease: The new vistas. Front. Med., 12.10.3389/fmed.2025.1494101 ↗
64. Arega, Y., and Shao, Y. (2022). Heart failure and late-onset Alzheimer’s disease: A Mendelian randomization study. Front. Genet., 13.10.3389/fgene.2022.1015674 ↗
65. Left Ventricular Ejection Fraction and Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease Pathology in Cognitively Normal Older Adults: The CABLE Study10.3233/JAD-201222 ↗
66. Murphy, J., Le, T.N.V., Fedorova, J., Yang, Y., Krause-Hauch, M., Davitt, K., Zoungrana, L.I., Fatmi, M.K., Lesnefsky, E.J., and Li, J. (2022). The Cardiac Dysfunction Caused by Metabolic Alterations in Alzheimer’s Disease. Front. Cardiovasc. Med., 9.10.3389/fcvm.2022.850538 ↗
67. Associations between coronary heart disease and risk of cognitive impairment: A meta-analysis10.1002/brb3.2108 ↗
68. Cerebral amyloid-β deposition in patients with heart disease or carotid occlusive disease: A systematic review and meta-analysis10.1016/j.jns.2023.120551 ↗
69. Atrial Fibrillation Is Associated with Cognitive Impairment, All-Cause Dementia, Vascular Dementia, and Alzheimer’s Disease: A Systematic Review and Meta-Analysis10.1007/s11606-021-06954-8 ↗
70. Alzheimer Disease Blood Biomarkers in Patients With Out-of-Hospital Cardiac Arrest10.1001/jamaneurol.2023.0050 ↗
71. Vascular pathology and pathogenesis of cognitive impairment and dementia in older adults
72. Cardiovascular Disease and Alzheimer’s Disease: The Heart–Brain Axis10.1161/JAHA.123.030780 ↗
73. Association of diabetes mellitus and dementia: The Rotterdam Study10.1007/s001250050588 ↗
74. Diabetes mellitus and the risk of dementia: The Rotterdam Study10.1212/WNL.53.9.1937 ↗
75. Diabetes mellitus as a risk factor for dementia in the Mexican elder population10.33588/rn.5307.2010628 ↗
76. Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus type-210.1016/j.jns.2009.09.022 ↗
77. Singh, D.D., Shati, A.A., Alfaifi, M.Y., Elbehairi, S.E.I., Han, I., Choi, E.-H., Yadav, D.K., Singh, D.D., Shati, A.A., and Alfaifi, M.Y. (2022). Development of Dementia in Type 2 Diabetes Patients: Mechanisms of Insulin Resistance and Antidiabetic Drug Development. Cells, 11.10.3390/cells11233767 ↗
78. Kong, Y., Wang, F., Wang, J., Liu, C., Zhou, Y., Xu, Z., Zhang, C., Sun, B., and Guan, Y. (2020). Pathological Mechanisms Linking Diabetes Mellitus and Alzheimer’s Disease: The Receptor for Advanced Glycation End Products (RAGE). Front. Aging Neurosci., 12.10.3389/fnagi.2020.00217 ↗
79. Kciuk, M., Kruczkowska, W., Gałęziewska, J., Wanke, K., Kałuzińska-Kołat, Ż., Aleksandrowicz, M., and Kontek, R. (2024). Alzheimer’s Disease as Type 3 Diabetes: Understanding the Link and Implications. Int. J. Mol. Sci., 25.10.3390/ijms252211955 ↗